# Oruka Therapeutics, Inc. (ORKA) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Oruka Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ORKA/mda/fy2025/): filed 2026-03-12; accession 0001213900-26-026929 (https://www.sec.gov/Archives/edgar/data/907654/000121390026026929/ea0273300-10k_oruka.htm); latest 10-K
- [FY 2024 MD&A](/company/ORKA/mda/fy2024/): filed 2025-03-06; accession 0001213900-25-021165 (https://www.sec.gov/Archives/edgar/data/907654/000121390025021165/ea0230445-10k_orukathe.htm)
- [FY 2023 MD&A](/company/ORKA/mda/fy2023/): filed 2024-02-01; accession 0000950170-24-009809 (https://www.sec.gov/Archives/edgar/data/907654/000095017024009809/abio-20231231.htm)
- [FY 2022 MD&A](/company/ORKA/mda/fy2022/): filed 2023-02-24; accession 0000950170-23-004379 (https://www.sec.gov/Archives/edgar/data/907654/000095017023004379/abio-20221231.htm)
- [FY 2021 MD&A](/company/ORKA/mda/fy2021/): filed 2022-03-14; accession 0001564590-22-010075 (https://www.sec.gov/Archives/edgar/data/907654/000156459022010075/abio-10k_20211231.htm)

Back to /company/ORKA/